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ALLERGIC ASTHMA IS A Th2 DISEASE
 
The profile of cytokine production by peripheral blood mono-
nuclear cells (PBMCs) from patients with bronchial asthma on
stimulation with house dust mite was demonstrated to be com-
patible with that of helper T type 2 (Th2) cells (1). The num-
ber of Th2 cells was also shown to be increased in bronchial
tissue and bronchoalveolar lavage fluid of patients with bron-
chial asthma. Also, the recruitment of allergen-specific Th2
cells from the peripheral blood into the bronchial tissue after
an inhalant allergen challenge was demonstrated. Allergic
asthma is therefore considered a Th2-driven disease in which
the presence of Th2 cells correlates with IgE production, mast
cell hyperplasia, and eosinophil infiltration, determining the
severity of the disease (2). The Th2-derived cytokine interleu-
kin 5 (IL-5) is a crucial cytokine, which accounts for the re-
cruitment and activation of eosinophils, resulting in airway
eosinophilia in patients with allergy (3). In animal models, de-
pletion of CD4
 
1
 
 T cells results in abrogation of airway eosino-
philia and in subsequent reduction of airway hyperresponsive-
ness. Similarly, elevated IL-4-induced serum levels of IgE and
allergen-specific IgE levels as observed in patients with atopic
allergy can be explained in terms of excessive Th2 activation.
Many, but not all, the pleiotropic effects of IL-4, which are of
importance in allergic diseases, can be inhibited by interferon 
 
g
 
(IFN-
 
g
 
). Thus, the balance between Th1/Th2 activation is gen-
erally established by determining the ratio between IL-4 and
IFN-
 
g
 
 produced by activated PBMCs or purified T cells.
 
COGNATE INTERACTION AND CYTOKINE-INDUCED 
ISOTYPE SWITCHING
 
IgE isotype switching in B lymphocytes requires physical in-
teraction of Th cells and B cells via surface molecules (prima-
rily CD40–CD40 ligand [CD40L]) and the presence of IL-4
and/or IL-13 secreted by Th2 cells (4). Immunoglobulin class
switching is generally considered a two-step process. In the
first step, the downstream target isotype-specific heavy chain
constant (C
 
H
 
) gene locus becomes transcriptionally active, re-
sulting in the synthesis of germline transcripts. This transcrip-
tional activity has been proposed to reflect the opening up of
the C
 
H
 
 locus, rendering it accessible to IL-4 and IL-13. The IL-4
promotor contains multiple binding sites for transcription fac-
tors, including the STAT-6 transcription induced by both IL-4
and IL-13. The second step in IgE switching requires the
CD40 molecule. Antigen-activated T–B cell cognate interac-
tions result in Th cell activation and expression of the CD40L,
facilitating interaction with CD40
 
1
 
 B cells that induces prolif-
eration and differentiation in an antigen-independent fashion.
The CD40 signal provides a strong proliferation signal, which
furthermore prevents the activated cells from undergoing apo-
ptosis. Likewise, human B cells stimulated with IL-4 in the
presence of CD40 cross-linking secrete detectable amounts of
IgG
 
4
 
 approximately 2 d earlier than IgE. On the basis of such
data it is hypothesized that the switch from IgM to IgE typi-
cally involves an initial switching to IgG
 
4
 
 (5). The relevance of
this sequential switching 
 
in vivo
 
 remains to be established.
The activating effect of IL-4 is promoted by IL-5 and IL-6,
but inhibited by IFN-
 
g
 
, transforming growth factor 
 
b
 
 (TGF-
 
b
 
),
and prostaglandin E
 
2
 
 (PGE
 
2
 
). Likewise, these mediators in-
hibit IL-4-induced expression of CD23 on B cells, indicating
that there is an association between CD23 expression and
IL-4-induced IgE production. Furthermore, IL-10 has a down-
modulating effect on the production of IFN-
 
g
 
. In T and B cell
cocultures of patients with an established allergy, the IgE pro-
duction was more dependent on endogenously produced
IL-13 than was the IgE production by control subjects, whereas
IL-4 neutralization resulted in equal inhibition of IgE produc-
tion in patients and control subjects. The contribution of IL-4
and IL- 13 to allergen-specific IgE production of human B
cells 
 
in vivo
 
 remains to be determined.
In allergic diseases it can be assumed that the abnormally
high levels of IgE antibodies in response to allergens are de-
rived from B cells that are abnormally stimulated or respond
abnormally to an allergenic stimulus. It has been observed
that when B cells from children with atopic diseases are cul-
tured 
 
in vitro
 
, they spontaneously synthesized 5,000 pg of IgE
per 10
 
6
 
 cells, whereas the same number of B cells from healthy
controls synthesized only 250 pg. It is as yet unresolved whether
this difference is due to an increased precursor frequency of
IgE-secreting B cells, an increased clone size, or an increased
production rate per cell.
 
IL-4 AND IL-4 RECEPTORS IN ATOPY
 
IL-4 has a critical role in the regulation of differentiation of
naive T cells into Th2 cells and the upregulation of IgE synthe-
sis. IL-4 is encoded on chromosome 5q31.1 in close proximity
to other cytokine genes (IL-3, IL-5, IL-9, IL-13, and granulo-
cyte-macrophage colony-stimulating factor [GM-CSF]) con-
tributing to the development of allergic inflammation and IgE
production. Genetic polymorphisms have been identified within
the regulatory elements of the IL-3, IL-4, and IL-9 genes be-
longing to the IL-4 gene cluster. The transcription of the IL-4
gene is regulated by multiple promoter elements that either in-
duce or suppress transcription. Thus, it has been demonstrated
that the human IL-4 promotor region exists in multiple allelic
forms, which differ in the level of IL-4 transcription and ex-
pression in T cells. Therefore, it is generally agreed that peo-
ple with asthma produce abnormally high amounts of IL-4 (6).
Currently, two different IL-4 receptors have been de-
scribed, one of which contains the 140-kD IL-4-binding pro-
tein (IL-4R
 
a
 
/CDw124), which dimerizes with the common 
 
g
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chain shared with the IL-2, IL-7, IL-9, IL-13, and IL-15 recep-
tor. Furthermore, IL-4R
 
a
 
 is able to associate with one of the
chains of the IL-13 receptor that comprises the type II IL-4 re-
ceptor. The role of the type II receptors on different cell types
is still the subject of research. The presence of the common 
 
g
 
chain in the type I receptor complex increases the binding af-
finity of IL-4 by two- to threefold and contributes to signal
transduction, including activation of the STAT-6 transcription
factor. A genetic polymorphism in the intracellular signaling
part of the IL-4 receptor has been identified whereby normal
levels of IL-4 may exert stronger biological effects resulting in
higher levels of, for example, IgE (7). This altered signaling
function of the receptor is strongly associated with atopy and
the underlying mutation may predispose susceptible persons
to allergic diseases.
 
ALLERGIC SENSITIZATION IN EARLY LIFE
 
It is generally appreciated that the prevalence of asthma is in-
creasing, and currently asthma affects one child in seven in
Western Europe (8). The reasons for this apparent increase
are suggested to include a better and earlier diagnosis, more
efficient treatment regimens, a shift from severe to more mild
disease, and an increased exposure to environmental aller-
gens. The T cell memory that develops against allergens is cur-
rently believed to be the result of complex interactions be-
tween genetic susceptibility and environmental factors. Such
factors as parental smoking, (viral) infections, (breast) feeding
methods, birthweight, elevated total IgE levels in cord blood,
early exposure to household pets, and inhalant allergens have
all been implicated to increase the risk of the development of
atopic disorders (2). The prevalence of atopic diseases in so-
called developed countries has risen over the past several de-
cades, which is too short a period for genetic change to take
place. Therefore, the environmental influence is much larger
than the hereditary component.
It has been proposed that the fetal immune system is
weakly skewed toward the preferential development of Th2-
type immune responses, as a result of the production of Th2-
promoting factors, such as IL-10 and PGE
 
2
 
, by the placenta (9,
10). Such an environment is, however, similar both for atopy-
prone and health nonatopic children. For the expansion and
increased activity of these Th2 cells, intrauterine allergen ex-
posure would be required. It is not understood how and to
what extent allergens can pass the placental barrier. It has
been recognized before that the placental barrier is not merely
a molecular sieve with a defined pore size, but is actively able
to transfer sometimes large molecules into the fetus. In the
transfer of specific IgG antibodies, the placenta could selec-
tively transfer antibodies on the basis of their idiotypic speci-
ficity.
After birth, house dust-mite specific stimulation revealed a
persisting Th2 response in atopic children, while nonatopic
children developed a gradual transition toward a preferential
Th1 response driven by the traditionally frequent exposure to
mycobacteria. In the Western world, lack of exposure to my-
cobacteria could be responsible for the increasing failure of in-
ducing such a Th1 development and, consequently, can ex-
plain the rise in atopic diseases observed over the last 25 yr.
Also, other observations suggesting a decline in viral and bac-
terial infections since the introduction of vaccination and the
development of antibiotics has resulted in a limitation of Th1
immune mechanisms and induced Th2 polarization, resulting
in an increasing prevalence of atopic diseases. On the basis of
 
in vitro
 
 analysis, selective outgrowth of a Th2 population
could be based on a preferential expansion of Th2 cells or the
relative absence or the selective inhibition of the activity of
Th1 cells. Evidence has led to both mechanisms being de-
scribed as playing a role in the development of allergic asthma
after birth. It remains to be established whether the increased
prevalence of allergic asthma needs to be explained in the cyto-
kine-dependent Th1–Th2 polarization or whether more shifts
from Th2
 
low
 
 to Th2
 
high
 
 activity may be sufficient. Also, the sug-
gested decreased interferon 
 
g
 
 (IFN-
 
g
 
) production in atopic
relative to nonatopic children needs to be confirmed. The con-
sequence of the absence of IFN-
 
g
 
 would be a decreased aller-
gen-specific delayed type hypersensitivity (DTH) response in
allergic versus nonallergic individuals, which could not be
found. The role of IFN-
 
g
 
 in atopic diseases is therefore impor-
tant beyond the mere Th1–Th2 paradigm.
Whereas the risk of contracting atopic disease during child-
hood is between 15 and 20% in the general population, it is in-
creased to 35 to 40% if the child’s mother has an atopic dis-
ease. The risk with two atopic parents increases to about 60%.
Children born to atopic mothers therefore constitute a high-
risk population and are well suited for the study of the impor-
tance of age-related changes in immune parameters that are
implicated in the expression of atopic diseases at the neonatal
stage. Although asthmatic diseases can start at any age, in
more than 50% of cases asthma symptoms start before the age
of 3 yr. The early onset of asthma determines the persistence
of the disease into adulthood, and is therefore considered an
important risk factor. Other important risk factors include ex-
posure to cigarette smoke, male sex, and viral infections, in-
cluding respiratory syncytial virus and parainfluenza virus. It
has been suggested that the immaturity of the immune system
together with completion of lung development at the neonatal
age might contribute to the mechanism of early atopic sensiti-
zation.
 
IMMATURITY OF THE NEONATAL IMMUNE SYSTEM
 
Accumulating evidence suggests that the immune system of
newborns is relatively immature as compared with adults,
which may fit into the concept of a window period with in-
creased susceptibility to develop atopy (11, 12). The capacity
of cord blood T cells to produce cytokines in response to aller-
gen-specific stimulation such as IFN-
 
g
 
 is strongly diminished,
which might be due to the presence of PGE
 
2
 
, an intrinsic defi-
ciency in the synthesis capacity, or an inefficient accessory cell
function. The lack of sufficient IFN-
 
g
 
 production may contrib-
ute to impaired neonatal antiviral responses and facilitate al-
lergic sensitization as the result of abnormal T cell function.
The Th2 cytokines were either expressed too weakly (IL-4) or
did not differ significantly (IL-5, IL-10). The secretion of im-
munoglobulins by B cells is strongly decreased while the num-
ber of CD23
 
1
 
 B cells is increased in newborns relative to
adults. This might explain the enhanced negative feedback reg-
ulation of IgE formation at the neonatal stage.
Moreover, antigen-presenting cells (APCs) are functionally
immature, related to their impaired phagocytosis and chemo-
taxis. Although it had originally been shown that high-dose
antigen exposure results in Th2 responses, atopic individuals
have a genetically based propensity to react with IgE antibody
formation to low doses of allergens that do not result in anti-
body formation in nonatopic subjects. On activation APCs
produce a plethora of cytokines that influence T cell polariza-
tion. Monocytes of atopic individuals have been shown to pro-
duce increased levels of PGE
 
2
 
 and reduced levels of IL-12.
The cognate interaction between the APC and the Th cell,
however, is complex and involves also the timing and strength
of costimulatory molecules, the strength of the interaction
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with the T cell receptor, and temporal changes in the produc-
tion of cytokines. What steps are crucially different between
atopic and nonatopic individuals has not been elucidated yet.
The percentages of peripheral blood CD4
 
1
 
 T cells express-
ing the activation markers CD25 and HLA-DR (human leu-
kocyte antigens) and CD8
 
1
 
 T cells expressing CD25 were ele-
vated in children with severe asthmatic disease. It is unclear
whether children with mild atopic disease display similar shifts
in expression of surface markers. Cord blood T cells display
no or decreased expression of CD40L on stimulation, which
together with the failure to express costimulatory cytokines
(IL-5, IL-6) might explain the poor immunoglobulin produc-
tion in the neonate. Most neonatal CD4
 
1
 
 T cells are immuno-
logically naive and express CD45RA (91%). These cells are
gradually replaced by CD45RO, a marker of activated or
memory T cells, as a result of repeated allergen exposure. The
latter cells are considered to be the high-rate cytokine-secret-
ing cells. In atopic adults, the percentage of CD45RO
 
1
 
 T cells
was significantly elevated compared with healthy control sub-
jects. Whether the same holds true for atopic children is not
known in detail.
 
THE INDUCTION OF TOLERANCE
 
As outlined above, helper T cell subset polarization is achieved
by two basic principles. First, each subset produces its own auto-
crine growth factors and, second, cytokines are produced that
cross-regulate the outgrowth of the counteracting subset. How-
ever, the observed skewing in subjects with allergic asthma to
the Th2 compartment may also result from other regulatory
processes. The preferential activation of Th2 cells could be the
result of active suppression of the Th1 subset due to the cyto-
kine-related interaction between T cell subsets and the APCs.
Unresponsiveness can be achieved by different mechanisms
including clonal deletion by apoptosis, by T cell anergy, or by
active suppression mediated by regulatory cells. These mecha-
nisms are not mutually exclusive, but may act synergistically.
The process of T cell anergy is best defined as a state of cel-
lular unresponsiveness in which the cell is alive but unable to
perform functional responses on restimulation. Anergized
cells are generated by antigen-specific T cell activation in the
absence of costimulatory molecules. This partial activation
signal renders these cells unable to proliferate and to secrete
IL-2. The main contributors of the costimulatory signals are
CD28 on the T cell and B7-1 (CD80) and B7-2 (CD86) on the
APC. This interaction enhances the transcription rate and sta-
bilization of IL-2 mRNA and increases the sensitivity of T cell
receptor (TCR) triggering. The B7 molecules possess still an-
other ligand, CTLA-4. This ligand has been shown to nega-
tively regulate T cell responses and to evoke a complete block
in the cell cycle progression and IL-2 production. CD28 ex-
pression on the T cell is constitutive, whereas CTLA-4 is in-
duced early after T cell activation. The differences in affinities
and binding kinetics with B7-1 and B7-2 determine whether a
cell becomes activated or remains unresponsive. The precise
role of APCs in tolerance induction is yet to be determined.
Clonal deletion of antigen-specific T cells and anergy are
both passive mechanisms regulating immune responses. The
ability to regulate helper T cell responses is important with re-
gard to Th1 cytokine production, because it has been shown that
excessive and sustained Th1 cytokine production may provoke
deleterious proinflammatory responses. Activation-induced
apoptosis is mediated by interaction of Fas ligand (FasL) with
its cognate receptor Fas. Th1 cells express high levels of FasL,
while Th2 cells express only low levels. Therefore, Th1 cells
are more sensitive to apoptosis and this property limits contin-
uous expansion of a proinflammatory Th1 response.
Regulatory T cells, on the other hand, mediate active sup-
pression (13, 14). These T cells comprise classic Th2 cells, ca-
pable of inhibiting Th1 responses, but also alternative T cell
populations. The mechanism of peripheral tolerance has been
focused mainly on the suppression of classic cell-mediated
type 1 responses and on animal models of diseases based on
excessive activity of Th1 cells. It is now clear that such toler-
ance induction is also active in humoral type 2 responses, such
as IgE production. Suppression becomes apparent after ad-
ministration of allergens via the oral, respiratory, and nasal
routes. One of the primary mechanisms of tolerance induction
is via secretion of immunosuppressive cytokines such as IL-10,
IL-4, and transforming growth factor 
 
b
 
 (TGF-
 
b
 
). As men-
tioned above, regulatory CD4
 
1
 
 T cell clones, isolated from 
 
in
vitro
 
 cultures, have appeared to produce low levels of IL-2 and
no IL-4, but high levels of IL-10 and TGF-
 
b
 
. When cocultured
with naive CD4
 
1
 
 T cells, these antigen-specific clones sup-
pressed the proliferative response to the same antigen. The
regulatory T cell clones themselves exhibited a low prolifera-
tive capacity. Neutralization of IL-10 and TGF-
 
b
 
 overcomes
this proliferative block. The activity of TGF-
 
b
 
-secreting regu-
latory T cells has been implicated as a component of oral tol-
erance, in recovery from experimental allergic encephalomy-
elitis, and in suppression of certain forms of inflammatory
colitis. TGF-
 
b
 
-deficient mice experience inflammation that af-
fects multiple organ systems, mainly the heart, liver, and lungs,
whereas IL-10 knockout mice produce a chronic enterocolitis.
This demonstrates the importance of these cytokines in regu-
lating and dampening the immune response.
Human counterparts of regulatory T cells have been pro-
posed in patients with severe combined immunodeficiency
(SCID), who after bone marrow reconstitution revealed high
numbers of IL-10 (but not IL-4)-producing CD4
 
1
 
 cells in
which IL-10 levels were associated with tolerance after allo-
genic stem cell transplantation. At present, it is unknown
whether these regulatory T cells are involved in the immuno-
pathology of allergic asthma by provoking excessive suppres-
sion of the Th1 compartment.
 
CHEMOKINES AND ADHESION MOLECULES 
IN ATOPIC DISEASES
 
Soluble factors, including chemokines, play an essential role in
leukocyte trafficking toward and infiltration of the airways of
individuals with asthma. CC chemokines have been implicated
in the immunopathology of allergic asthma by their chemotactic
and stimulatory activity and their ability to induce degranula-
tion and histamine release from basophils. The CC chemokines
RANTES (regulated on activation, normal T cell expressed
and presumably secreted) and monocyte chemoattractant pro-
tein (MCP)-3 act on eosinophils, whereas MCP-1, MCP-3, and
RANTES affect basophil functions. Some reports have de-
scribed chemotactic proteins responsible for directing Th2
lymphocytes toward allergic airways. Interestingly, the major
contributor to this process is not a traditional chemokine, but
the interleukin IL-16 (15). This interleukin is released in re-
sponse to allergens, mitogen, histamine, or serotonin by CD8
 
1
 
T cells, eosinophils, and airway epithelial cells and possibly
CD4
 
1
 
 T cells. IL-16 chemotactically attracts CD4
 
1
 
 T cells,
eosinophils, and monocytes by interacting with the CD4 mole-
cule. In patients with asthma, IL-16 was detected in the bron-
choalveolar lavage (BAL) fluid 6 h after allergen challenge. In
fact, 80% of the chemotactic activity is ascribed to IL-16,
whereas the remaining activity is due to the CC chemokine
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macrophage inflammatory protein 1
 
a
 
 (MIP-1
 
a
 
). The involve-
ment of eotaxin in the process of Th2 trafficking has been pro-
posed as well. It was shown that after 
 
in vitro
 
 polarization of
CD4
 
1
 
 T cells, the Th2-polarized cells showed a higher expres-
sion of the eotaxin ligand CCR3. Hypothetically, this implies
that once eotaxin is released within inflamed airways, Th2
cells (but not Th1 cells) are selectively attracted toward the site
of inflammation, resulting in progressive polarization of the lo-
cal Th2 cell response.
Adhesion molecules, such as intracellular adhesion mole-
cule 1 (ICAM-1) and E-selectin, the membrane-bound form
of soluble E-selectin, are cell surface adhesion molecules that
are expressed on endothelial cells during inflammatory pro-
cesses and determine leukocyte recruitment and trafficking
into inflamed tissues (16). Therefore, the soluble forms of these
adhesion molecules, generated by alternative splicing or pro-
teolytic cleavage, generally correlate with the degree of inflam-
matory infiltrates, thereby providing useful parameters for
monitoring the disease severity and successful therapeutic in-
terventions. In asthma, increased bronchial epithelium expres-
sion of ICAM-1 was found with a concomitant presence of in-
creased serum levels of soluble ICAM-1. Despite these finding
the role of ICAM in the pathogenesis of asthma remains to be
established.
 
CONCLUSION
 
It has been proposed that expression of Th2-polarized immu-
nity to inhaled (environmental) allergens at the level of the
airway mucosa is typical of the pathogenesis of atopic respira-
tory disease. At birth, there is evidence of a resting, but previ-
ously (
 
in utero
 
) activated, memory T cell population that
could be responsible for the rapid release of cytokines after
neonatal allergen exposure. Generally, this neonatal atopic
predisposition is expressed within the first 1 to 2 yr of life.
During this period, the immune system is also gradually ma-
turing and is highly flexible. This property potentially results
in the induction of clinical symptoms of atopic disease, the al-
lergy window period. Gradually the immune system estab-
lishes control over the neonatal immune responses, which can
take the first 5 yr of life. However, it remains to be established
to what degree expression of food allergic symptoms during
the first year of life is related to the probability of developing
inhalation allergy at ages above 3 yr, as there are conflicting
data published. These findings open possibilities to link immu-
nopathological changes evident in the first few years of life to the
development of asthma-like symptoms extending into adult-
hood. Such research is, however, dependent on the unequivo-
cal diagnosis of asthma at the age of 5–6 yr. Developments
have made essential lung function measurements possible at
this age and this facilitates proper asthma diagnosis.
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DISCUSSION
 
Holt:
 
 We too observed that it is key to be extremely careful in
handling of the cells up to the final processing. We have
worked out a protocol that involved putting the cells into an
appropriate transport medium. We shipped cells regularly be-
tween Perth and Melbourne and Dr. Björkstén is using the
same system to ship cells between Dublin and Linköping. It is
important to do the appropriate controls, but that part of the
story is solvable. With respect to the defect in interferon 
 
g
 
production, this is not an absolute defect. You don’t see an ef-
fect until you look at the relative levels of production as a
function of age. Would you agree with that?
 
Savelkoul:
 
 Yes. We observed the IFN-
 
g
 
 defect in some chil-
dren, but it is certainly not absolute. The decreased IL-10 lev-
els we see in combination with the increased IL-4 expression
are very interesting, since these cells clearly are not Th2 cells.
The decreased IL-10 production resembles that in IFN-
 
g
 
 pro-
duction, although we don’t know whether it is based on the
same intrinsic defect.
We observe this defect under some conditions, but not in
all children. The point I want to make is that there is variabil-
ity. How that is regulated we don’t know. There might be dif-
ferences in chaperone proteins that help in the transport over
the cell membrane.
 
Holt:
 
 We are also becoming very interested in IL-10. We have
been looking at the relationship between the magnitude in the
skin test response in children at various ages in relation to the
size of the IL-10 response and indeed we see a very strong neg-
ative relationship, which would argue just as you have done
that there is important negative feedback 
 
in vivo
 
 by IL-10.
 
Savelkoul:
 
 I fully agree with that. Under many conditions you
find after stimulation a little bit of IL-4 and a lot of IL-10. Peo-
ple tend to dichotomize the T cell system and say: These are
Th2 cells. However, it takes 3 or 4 days before these cells are
 S104
 
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 162 2000
 
generated 
 
in vitro
 
. So, initially they need IL-4 and finally they
may produce only IL-10. If one uses a single stimulus with a
heterogenous population of cells, it is too easy to propose a
Th2 response after reading out three or four cytokines that are
associated with the Th2 phenotype.
 
Björkstén:
 
 We can also confirm the IL-10 story. We see high
levels of IL-10 in atopic dermatitis patients with negative skin
prick tests, while the IL-4 levels are similar in skin test-posi-
tive and negative subjects. you found that the cord blood cells
were activated. Is this the birth in itself? Have you studied ba-
bies born by caesarean section?
 
Savelkoul:
 
 No. We do not know what is due to the phenotype
and what is induced by the stress during birth. I agree that
birth has a profound influence on cytokine levels, but this can-
not easily explain the observed shift in the cellular composi-
tion of the cord blood.
 
Vercelli:
 
 The presence of 
 
«
 
 germline transcripts in B cells of
nonallergic or not-yet allergic children as well as in B cells of
allergic children implies a two-hit model for IgE production.
What is the second hit that would take the cells from the ex-
pression of 
 
«
 
 germline transcripts to actually switching?
 
Savelkoul:
 
 We don’t know. We have to examine more kids. In
these studies only 10–15 children were analyzed, but in the co-
hort of Dr. Van der Laan we have cells available to run this in
a much larger set of children. We would also like to study IgG
 
4
 
germline transcripts.
 
Out:
 
 You showed that T cells in cord blood from the high-risk
babies were more activated than those from controls. Yester-
day, Dr. Holt showed us that T cell clones were generated in a
lower frequency from the cord blood from babies that became
atopic in later life and that these clones produced lower
amounts of IL-4 and IFN-
 
g
 
. Do you consider this as a differ-
ence between your results and his? And to Dr. Holt: Could it
be an explanation that the already-activated cells do not grow
out into T cell clones, thereby missing the activated cells in
this analysis?
 
Savelkoul:
 
 You have to remember that the data I showed you
are after polyclonal stimulation, while Dr. Holt’s data are after
antigen-specific stimulation. We have also accumulated anti-
gen-specific stimulation data, but we are still processing these,
so I can’t answer now.
 
Platts-Mills:
 
 Since the cord blood cells are so active, how can
you be sure that allergen-specific responses is not actually a
mitogeneic response?
 
Savelkoul:
 
 That is very true. That will be very hard to segre-
gate. Maybe Dr. Holt could comment.
 
Platts-Mills:
 
 It has always been difficult to understand why
there should be a good allergen-specific response in the cord
blood and at 6 months it disappears.
 
Holt:
 
 We don’t see all this activation. So, all I can suggest is
that it may be due to major differences between the popula-
tions that we are looking at, 75–85% of our kids are delivered
by caesarean section; we have never looked at the obvious
comparisons. But, I don’t think that is it, because we just do
not see high backgrounds in terms of proliferation. When we
are talking about looking at allergen-specific responses we are
talking about 100 dpm as our background in terms of prolifer-
ation. Maybe it is Yssel’s medium that is the problem in that
context. It has never been an issue with us.
 
Savelkoul:
 
 I cannot exclude that. Hopefully, the allergen-spe-
cific data will tell us more. However, I don’t think it is some-
thing purely technical, as we have found the increased popula-
tion of CD4
 
1
 
CD45RA
 
1
 
 in cord blood as well.
